BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35561314)

  • 1. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.
    Narkhede M; Goyal G; Shea L; Mehta A; Giri S
    Blood Adv; 2022 Jul; 6(14):4122-4131. PubMed ID: 35561314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
    Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
    J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era.
    Mathys A; Bacher U; Banz Y; Legros M; Mansouri Taleghani B; Novak U; Pabst T
    Hematol Oncol; 2022 Apr; 40(2):292-296. PubMed ID: 34817087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
    Mei MG; Cao TM; Chen L; Song JY; Siddiqi T; Cai JL; Farol LT; Al Malki MM; Salhotra A; Aldoss I; Palmer J; Herrera AF; Zain J; Popplewell LL; Chen RW; Rosen ST; Forman SJ; Kwak L; Nademanee AP; Budde LE
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1861-1869. PubMed ID: 28733266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG
    Curr Treat Options Oncol; 2018 Jul; 19(9):45. PubMed ID: 30032463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.
    Robak T; Smolewski P; Robak P; Dreyling M
    Leuk Lymphoma; 2019 Nov; 60(11):2622-2634. PubMed ID: 31018735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
    Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment for mantle cell lymphoma].
    Izutsu K
    Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
    Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
    Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
    Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.
    Aurer I
    Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
    Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
    Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in
    Lew TE; Cliff ERS; Dickinson M; Tam CS; Seymour JF; Blombery P; Bajel A; Ritchie D; Khot A
    Leuk Lymphoma; 2023; 64(11):1792-1800. PubMed ID: 37531077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M; Kahl BS
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.